A Phase 2 interventional study of Mesenchymal Stromal Cells (MSC) and placebo in Traumatic Brain Injury, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 3 sites in France. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.
Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Brain Injuries, Traumatic by Assistance Publique - Hôpitaux de Paris — 6 open to participants now, 7 under way, none of them phase 3. Brain Injuries, Traumatic · Assistance Publique - Hôpitaux de Paris.
Among the 15 studies in Brain Injuries, Traumatic by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2024, is one of 2 in phase 2, and was the 13th registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →6 of the 15 studies in Brain Injuries, Traumatic by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–65
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–80
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
Assistance Publique - Hôpitaux de Paris
Ages 18+
By country, each count listing its studies:
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 50 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2024.
This study's planned enrollment of 68 is above the median of 52 across 1,091 interventional studies indexed under Brain Injuries, Traumatic.
Median enrollment 67 across the 8 interventional studies, 118 across the 7 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
2 of the studies in Brain Injuries, Traumatic by Assistance Publique - Hôpitaux de Paris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04534777Assistance Publique - Hôpitaux de ParisMultimodal Neuroprognostication in Disorders of Consciousness | 2027-05 |
| NCT06146062Assistance Publique - Hôpitaux de ParisEffects of Intravascular Administration of Mesenchymal Stromal Cells Derived from Wharton's Jelly of the Umbilical Cord on Systemic Immunomodulation and Neuroinflammation After Traumatic Brain Injury. | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 15 studies in Brain Injuries, Traumatic by Assistance Publique - Hôpitaux de Paris, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Traumatic brain injuries (TBI) are one of the leading causes of death and disability worldwide. These patients are burdened by physical, cognitive, and psychosocial deficits, leading to an important economic impact for society. Treatments for TBI patients are limited and none has been shown to provide prolonged and long-term neuroprotective or neurorestorative effects. TBI related disability is linked to the severity of the initial injury but also to the following neuroinflammatory response which may persist long after the initial injury.
Moreover, a growing body of evidence suggests a link between TBI-induced neuro-inflammation and neurodegenerative post traumatic disorders. Consequently, new therapies triggering immunomodulation and promoting neurological recovery are the subject of major research efforts.
In this context, mesenchymal cell-based therapies are currently investigated to treat various neurological disorders due to their ability to modulate neuroinflammation and to promote simultaneous neurogenesis, angiogenesis, and neuroprotection.
Clinical trials using intravenous MSC have been conducted for various pathologies, all these studies showing a good safety profile.
The hypothesis of the study is that intravenous repeated treatment with MSC derived from Wharton's Jelly of the umbilical cord may be associated with a significant decrease of post-TBI neuroinflammation and improvement of neuroclinical status.
The main objective of the study is to evaluate the effect of iterative IV injections of MSC on post-traumatic neuroinflammation measured in corpus callosum by PET-MRI at 6 months in severe brain injured patients unresponsive to simple verbal commands 5 days after sedation discontinuation.
Traumatic brain injuries (TBI) are one of the leading causes of death and disability worldwide. These patients are burdened by physical, cognitive, and psychosocial deficits, leading to an important economic impact for society. Treatments for TBI patients are limited and none has been shown to provide prolonged and long-term neuroprotective or neurorestorative effects. TBI related disability is linked to the severity of the initial injury but also to the following neuroinflammatory response which may persist long after the initial injury.
Moreover, a growing body of evidence suggests a link between TBI-induced neuro-inflammation and neurodegenerative post traumatic disorders. Consequently, new therapies triggering immunomodulation and promoting neurological recovery are the subject of major research efforts.
In this context, mesenchymal cell-based therapies are currently investigated to treat various neurological disorders due to their ability to modulate neuroinflammation and to promote simultaneous neurogenesis, angiogenesis, and neuroprotection. Indeed, several experimental studies have reported that human umbilical cord-derived mesenchymal stromal cells (MSC) have the ability to improve neurological outcomes and recovery in cerebral injury animal models, including TBI.
Clinical trials using intravenous MSC have been conducted for various pathologies, all these studies showing a good safety profile. In TBI, small clinical trials using different modalities for administration of mesenchymal cells are available but none about MSC derived from Wharton's Jelly of the umbilical cord.
The hypothesis of the study is that intravenous repeated treatment with MSC derived from Wharton's Jelly of the umbilical cord may be associated with a significant decrease of post-TBI neuroinflammation and improvement of neuroclinical status.
The main objective of the study is to evaluate the effect of iterative IV injections of MSC on post-traumatic neuroinflammation measured in corpus callosum by PET-MRI at 6 months in severe brain injured patients unresponsive to simple verbal commands 5 days after sedation discontinuation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
20 healthy volunteers will be included for MRI normalization Volunteer eligibility criteria
Inclusion criteria :
Exclusion criteria :
for MRI and PET-MRI
Patient unable to remain supine and motionless during the duration of the examination
68 severe TBI patients with the following inclusion and exclusion criteria will be included"
Patient Inclusion criteria
Severe TBI defined by:
Patient Exclusion criteria
Contraindication for MRI and PET-MRI:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Final product is a MSC solution at the concentration of 2.10\^6/kg in 150 mL of NaCl 0.9% and human albumin 0.5%, conditioned aseptically and identified for IV administration. 3 injections one week apart.
Drug: Mesenchymal Stromal Cells (MSC)
The placebo will be a solution of NaCl 0.9% 3 injections one week apart.
Drug: placebo
3 injections one week apart
3 injections one week apart
effect of iterative IV injections of WJ-UC-MSC on post-traumatic neuroinflammation
\[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in corpus callosum (Region of Interest, ROI) measured by dynamic PET-MRI
Time frame: 6 months after the last injection
radiological markers from PET-MRI_1
The regional fractional anisotropy (FA) from DTI acquisition of PET-MRI
Time frame: 6 months after the last injection
radiological markers from PET-MRI_2
The mean diffusibility (MD) from DTI acquisition of PET-MRI
Time frame: 6 months after the last injection
Treatment feasibility
number of treatments administrated to the patient
Time frame: at the third injection
Neurological clinical Score M6
Glasgow Outcome Scale-Extended
Time frame: 6 months after the last injection
Neurological clinical Score M12
Glasgow Outcome Scale-Extended
Time frame: 12 months after the last injection
cognitive assessment M6
MOCA scale
Time frame: 6 months after the last injection
cognitive assessment M12
MOCA scale
Time frame: 12 months after the last injection
short term Tolerance D10
Common Terminology Criteria for Adverse Events
Time frame: 10 days after the last injection
long term Tolerance M6
Common Terminology Criteria for Adverse Events
Time frame: 6 months after the last injection
long term Tolerance M12
Common Terminology Criteria for Adverse Events
Time frame: 6 months after the last injection
neuroinflammation of pericontusional
\[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in pericontusional
Time frame: 6 months after the last injection
neuroinflammation of grey matter
\[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in grey matter
Time frame: 6 months after the last injection
neuroinflammation of white matter
\[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in white matter
Time frame: 6 months after the last injection
neuroinflammation of frontal area
\[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in frontal area
Time frame: 6 months after the last injection
neuroinflammation of parietal area
\[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in parietal area
Time frame: 6 months after the last injection
neuroinflammation of occipital area
\[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in occipital area
Time frame: 6 months after the last injection
neuroinflammation of hippocampus
\[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in hippocampus,
Time frame: 6 months after the last injection
neuroinflammation of thalamus
\[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in thalamus,
Time frame: 6 months after the last injection
neuroinflammation of mesencephalus
\[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in mesencephalus
Time frame: 6 months after the last injection
neuroinflammation of cerebellum
\[18F\]-DPA-714 Standard Uptake Value ratio (SUVr) in cerebellum
Time frame: 6 months after the last injection
Cytokine and chemokine levels in plasma
Luminex magnetic beads technology
Time frame: 6 months after the last injection
PBMC profile
High-dimensional characterization of immune reprogramming during the treatment by single-cell RNA-sequencing of PBMC.
Time frame: 6 months after the last injection
Transcriptomics and regulatory epigenomics of circulating monocytes and lymphocytes 1.
H3K27ac
Time frame: 6 months after the last injection
Transcriptomics and regulatory epigenomics of circulating monocytes and lymphocytes 2.
H3K4me3
Time frame: 6 months after the last injection
Transcriptomics and regulatory epigenomics of circulating monocytes and lymphocytes 3.
ChIP-seq
Time frame: 6 months after the last injection
Transcriptomics and regulatory epigenomics of circulating monocytes and lymphocytes 4.
ATAC-seq
Time frame: 6 months after the last injection
Genome-wide single-nucleotide polymorphism (SNP) genotype.
DNA sample
Time frame: After 1 injection
Analyze the pharmacokinetics and pharmacodynamics of CSM WJ-UC in humans 1
NGS approach,
Time frame: After 3rd injection 48 hours later
Analyze the pharmacokinetics and pharmacodynamics of CSM WJ-UC in humans 2
digital droplet (dd)-PCR approach,
Time frame: After 3rd injection 48 hours later
Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration. 1
populations of immune effector cells, such as Tregs,
Time frame: After 3rd injection 48 hours later
Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration.2
populations of immune effector cells, such as Teff,
Time frame: After 3rd injection 48 hours later
Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration.3
populations of immune effector cells, such as NK cells,
Time frame: After 3rd injection 48 hours later
Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration. 4
populations of immune effector cells, such as NKT,
Time frame: After 3rd injection 48 hours later
Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration. 5
populations of immune effector cells, such as MAIT,
Time frame: After 3rd injection 48 hours later
Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration. 6
populations of immune effector cells, such as DC
Time frame: After 3rd injection 48 hours later
Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration. 7
populations of immune effector cells, such as monocytes
Time frame: After 3rd injection 48 hours later
Deep phenotyping of the main immune effector cell populations humans, to identify the phenotypes involved in immunomodulation and alloimmunization induced by MSC administration. 8
populations of immune effector cells, such as B cells.
Time frame: After 3rd injection 48 hours later
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Aug 2027, 38 months after the start.
Of 47 phase 2 interventional studies under Brain Injuries, Traumatic, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 30. This study's planned 38 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →